GlassScriptPhysician profile
Yao Der E Shieh
NPI 1881321123
$1,812.39
in general payments reported to CMS, 2019-2025
18 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.62 · 2023: $431 · 2024: $627 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $475.56 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $240.80 | 2025 | Winrevair, Verquvo |
| Novartis Pharmaceuticals Corporation | $217.59 | 2022-2025 | |
| Pfizer INC. | $192.75 | 2024-2025 | |
| Novo Nordisk INC | $90.18 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $80.92 | 2023-2024 | Arexvy |
| Boston Scientific Corporation | $75.62 | 2024-2025 | Cds Broad Portfolio Offering |
| Amgen INC. | $73.83 | 2023-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $54.62 | 2023 | Austedo |
| Kiniksa Pharmaceuticals International, Plc | $54.44 | 2024 | Arcalyst |
| Lilly USA, LLC | $50.25 | 2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $44.78 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $40.61 | 2024 | Airsupra |
| Exact Sciences Corporation | $36.50 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $26.93 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.48 | 2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $21.46 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yao Der Shieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.